<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154778</url>
  </required_header>
  <id_info>
    <org_study_id>910703</org_study_id>
    <nct_id>NCT00154778</nct_id>
  </id_info>
  <brief_title>Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the response rate of Paclitaxel combination&#xD;
      chemotherapy with UFT and Leucovorin in patients with advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since 1982,cancer has been the leading cause of death in Taiwan. In particular,gastric cancer&#xD;
      is the fourth leading cause of death in male cancer patients and the sixth for female&#xD;
      patients in 2000,accounting for an estimated 2,374 deaths. In recent years, the treatment of&#xD;
      gastric cancer patients has gradually been improving due to advances in early diagnosis and&#xD;
      surgical techniques. Although chemotherapy and radiation therapy have been used in either the&#xD;
      adjuvant or palliative setting, their values are still limited due to their unacceptable&#xD;
      toxicity or inadequate efficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the response rate</measure>
    <time_frame>2003~2004</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine time to progression and safety</measure>
    <time_frame>2004~2005</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxol, UFT,Leucovorin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old&#xD;
&#xD;
          2. Patients with histologically confirmed gastric adenocarcinoma, defined as locally&#xD;
             advanced unresectable or metastatic or recurrent disease&#xD;
&#xD;
          3. Patients with at least one measurable lesion&#xD;
&#xD;
          4. ECOG performance status of 0,1 or 2&#xD;
&#xD;
          5. Patients with no prior chemotherapy and radiotherapy for metastatic disease (patients&#xD;
             who have received and completed prior adjuvant chemotherapy at least 6 months prior to&#xD;
             study enrollment may be enrolled into the study, prior taxane chemotherapy should be&#xD;
             excluded)&#xD;
&#xD;
          6. Patients with physiological functions (bone marrow, heart, liver, kidney, etc.)&#xD;
             meeting the following criteria: WBC &gt;4000/mm3, ANC &gt;1500/mm3, PLT &gt;100,000/mm3, Hb&#xD;
             &gt;9.0g/dL, ALT&lt;3 times the ULN (&lt;5 times the ULN for liver metastasis cases), Total&#xD;
             bilirubin &lt;1.5mg/dL, Creatinine &lt;the upper limit of normal&#xD;
&#xD;
          7. Accessible for treatment and follow-up&#xD;
&#xD;
          8. Give written informed consent&#xD;
&#xD;
          9. Women of child bearing potential must have a negative plasma or urine pregnancy test&#xD;
             within 72 hours prior to start of the study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received surgery within 14 days prior to enrollment&#xD;
&#xD;
          2. Patients with CNS metastasis&#xD;
&#xD;
          3. History of hypersensitivity related to the administration of&#xD;
             polyoxyethylated-castor-oil (cremophor EL)-containing preparation (e.g.&#xD;
             cyclosporin,etc.) or hardened-castor-oil-containing preparation (e.g. vitamin&#xD;
             preparation for injection,etc.)&#xD;
&#xD;
          4. Patients with a history of severe hypersensitivity&#xD;
&#xD;
          5. Active infectious symptoms&#xD;
&#xD;
          6. Patients with active gastrointestinal bleeding, intestinal obstruction or other&#xD;
             situation that dose not allow oral intake of medication&#xD;
&#xD;
          7. Patients with ascites that adversely affects performance status&#xD;
&#xD;
          8. Pre-existing CTC Grade 2 or greater neuropathy (motor or sensory)&#xD;
&#xD;
          9. Pregnant or nursing females&#xD;
&#xD;
         10. Patients who have participated in other clinical trials within 30 days prior to the&#xD;
             first dose of the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Huei Yeh, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Nationa Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&amp;db=PubMed&amp;term=16804524</url>
    <description>An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.</description>
  </link>
  <results_reference>
    <citation>Chao Y, Li CP, Chao TY, Su WC, Hsieh RK, Wu MF, Yeh KH, Kao WY, Chen LT, Cheng AL. An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer. 2006 Jul 17;95(2):159-63. Epub 2006 Jun 27.</citation>
    <PMID>16804524</PMID>
  </results_reference>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>July 30, 2007</last_update_submitted>
  <last_update_submitted_qc>July 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2007</last_update_posted>
  <keyword>Combination,Chemotherapy,Advanced Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

